| Autor: |
Alexdóttir, Marta S., Bourgonje, Arno R., Karsdal, Morten A., Bay-Jensen, Anne-Christine, Faber, Klaas Nico, Loveikyte, Roberta, van Dullemen, Hendrik M., Visschedijk, Marijn C., Festen, Eleonora A. M., Weersma, Rinse K., Dijkstra, Gerard, Mortensen, Joachim H. |
| Přispěvatelé: |
Center for Liver, Digestive and Metabolic Diseases (CLDM), Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Groningen Institute for Organ Transplantation (GIOT), Translational Immunology Groningen (TRIGR) |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Zdroj: |
Journal of Crohn's and Colitis, 15(Suppl(1)), S403-S404. Oxford University Press |
| ISSN: |
1873-9946 |
| Popis: |
Background Immunotherapeutic drugs such as anti-TNFα antibodies have greatly improved the treatment of inflammatory bowel disease (IBD). However, up to 20-40% of patients still fail to respond to therapy as the pattern of disease is variable. Better patient profiling could increase treatment response and improve quality of life. The aim of this study was to assess whether serological biomarkers reflecting tissue formation and different forms of basement membrane (BM) degradation could monitor or predict treatment response to anti-TNFα in patients with Crohn’s disease (CD) and Ulcerative Colitis (UC). Methods Using competitive ELISA, serum biomarkers of matrix metalloproteinase (MMP)-mediated type IV collagen degradation (C4M), T-cell related collagen degradation (C4G) and type III and IV collagen formation (PRO-C3, PRO-C4) were measured in 89 patients (CD=63, UC=26) receiving infliximab (IFX) induction therapy. Disease activity was defined by composite assessment of the Harvey-Bradshaw Index (HBI) for CD and Simple Clinical Colitis Activity Index (SCCAI) for UC together with physician’s global assessments (PGA). Clinical remission (HBI |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
